Market Overview:

The Global Artificial Vascular Grafts Market Is Projected To Grow At USD 1.81 Billion By 2022 And USD 3.12 Billion With CAGR Of 5.14% During The Forecast Period From 2022 To 2030.

Vascular graft, also called vascular bypass, is a procedure that reconnects blood vessels to move blood from one area to another. Most of the time, a vascular graft is used to get around an infected artery by going from a normal bloodstream area to another normal bloodstream area. It is often done when the body doesn't get enough blood (ischemia) because of atherosclerosis, during organ transplantation, or as part of hemodialysis.

Vascular grafting is used to treat problems with the blood vessels, like coronary artery disease (CAD), pulmonary embolism (blood clots), deep vein thrombosis (DVT), chronic venous insufficiency (CVI), and congenital heart defects in children (CCDs). Vascular diseases are caused by things like high blood pressure, cholesterol buildup, heart damage, and infections. Vascular diseases are more likely to happen if you have diabetes, high blood pressure, are overweight, drink a lot of alcohol, or smoke cigarettes. The materials used to make the synthetic vascular grafts are expanded polytetrafluoroethylene, Dacron, and polyurethane. But polyurethane is better able to match the flexibility of the body's own blood vessels. In most vascular grafting procedures, hemodialysis access grafts, endovascular aneurysm repair stent grafts, and peripheral vascular grafts are used.

Market Dynamics:

Market Trends:

• Increasing Incidence of Cardiovascular Diseases

Cardiovascular disease (CVD) is the main factor in the growth of the vascular graft market. As CVD gets worse, the arteries and veins start to narrow, which blocks blood vessels and reduces blood flow to the body's vital organs. This could lead to heart attack, coronary artery disease, or a heart stroke, all of which are very dangerous.

For example, in October 2022, heart disease will be the leading cause of death in the U.S., killing about 697,000 people. In the U.S., one person will die of heart disease almost every 34 seconds. Vascular grafts are important because they are used to get around broken blood vessels and keep the blood flowing. Because of all of these things, the market for vascular grafts will grow over the next few years.

Driving Factors:

• Increasing incidence of ESRD

The University of California says that about 2 million people around the world have ESRD. About 650,000 people in the US are diagnosed with ESRD every year. At the moment, ESRD is most common in Japan, Taiwan, Mexico, the United States, and Belgium.

Dialysis is the only option for people with ESRD who don't want to get a kidney transplant. Three times a week, a treatment called hemodialysis is done. Due to long-term dialysis, many patients' superficial veins are worn out, and vascular grafts are still the only way to keep doing hemodialysis.

Also, the National Institute of Diabetes and Digestive and Kidney Diseases says that about 14% of people in the US have CKD as a whole. Over 0.6 million people in the United States have kidney failure. About 0.4 million of these people are on dialysis.

• Advancements in Medical Technology

Artificial vascular grafts have been made in new and better ways thanks to improvements in medical technology. Now, these grafts have better biocompatibility, durability, and functionality, which means they are better for patients. The number of options on the market has grown as materials, ways of making things, and bioengineering methods keep getting better.

• Increase in Number of Lifestyle-related Disorders 

Diabetes, high blood pressure, and obesity are just some of the lifestyle-related diseases that are becoming more common. This is because people are eating poorly and not exercising enough. According to the International Diabetes Federation (IDF), about 527 million adults around the world had diabetes in 2021. This number is expected to rise to 643 million by 2030 and 783 million by 2045. Hypertension, or high blood pressure, is another disorder that can be caused by eating poorly or too much salt, not being active enough, or being overweight or obese.

The WHO says that about 1.28 billion adults between the ages of 30 and 79 have high blood pressure. Most of these people live in low- and middle-income countries. So, the rise in lifestyle-related diseases among people around the world is driving up the need for hospitalization, which in turn is increasing the global demand.

Restraints/Challenges:

• Product Failures and Recalls

When a product doesn't work as it should, it can cause serious or even fatal problems for patients. Over the years, many products have been taken off the market because they didn't work right or because of other problems. Changes in the market can make it harder for end users to believe that grafts are safe, which can make it harder to use them in treatment.

• High Cost

Artificial vascular grafts can be more expensive than grafts made from the patient's own blood vessels. The price is higher because it costs more to make, uses more expensive materials, and has more advanced technology. Artificial vascular grafts can be hard to get if they are too expensive, especially in places where there aren't enough medical resources or where insurance doesn't cover enough.

• Limited Clinical Evidence

Even though artificial vascular grafts have been used in clinical settings for a number of years, there may not be enough long-term clinical data and evidence to prove that they are as safe and effective as traditional grafting methods. When doctors and surgeons think about using artificial vascular grafts, this can make them hesitant.

Opportunities:

• Emerging Markets

Players in the vascular grafts market can expect to see a lot of growth in emerging markets like Australia, Singapore, Japan, and China. The NCBI says that between 2007 and 2015, in Japan, 985 out of 999 people who had EVAR were older than 50. Since Japan has the most elderly people, more aortic aneurysms will happen as this group grows. The Ministry of Internal Affairs and Communications estimated in 2014 that 33.0% of the Japanese population is over the age of 60. By 2050, about 40% of Japan's people are expected to be over 65.

• The Growing Geriatric Population 

The global vascular graft market will grow because there are more older people, who are more likely to get heart diseases like peripheral artery disease, coronary artery disease, and aortic aneurysm. For example, a report from the World Health Organization (WHO) in 2022 says that by 2030, 1 in 6 people in the world will be 60 or older, and the number of people in this age group will have grown from 1 billion in 2020 to 1.4 billion. Also, by 2050, the number of people 60 and older around the world is expected to double, to 2.1 billion.

Also, as technology has improved, the vascular graft procedure has become more effective and less invasive. This means that older people can have procedures with fewer problems. So, the growing number of older people will have a big effect on the growth of the global vascular graft market over the next few years.

• Technological Innovations

As materials science, bioengineering, and manufacturing techniques continue to improve, it might be possible to make better artificial vascular grafts. Bioresorbable grafts, grafts made with nanotechnology, and tissue-engineered grafts could improve biocompatibility, reduce complications, and lead to better long-term results.

Strategic Development:

• In October 2017 - The FDA gave Medtronic permission to use the Heli-FX EndoAnchor system with the Medtronic Endurant II/IIs thoracic stent graft system.
• In April 2017 - Endologix Inc. made a deal with Deerfield Management, a top healthcare investment firm, to give USD 170 million in funding.
• In January 2017 - The CE Mark for the AFX and AFX 2 Endovascular AAA System was brought back.
• In May 2022 - Aijun Wang, a professor at UC Davis, got a $3 million grant from the California Institute for Regenerative Medicine (CIRM) to work on making a smart, long-lasting vascular device for hemodialysis patients with renal failure who use hemodialysis.
• In August 2022 - W. L. Gore & Associates bought InnAVasc Medical, a privately held company that makes medical technology. W. L. Gore & Associates is a global material science company that wants to change industries and make people's lives better. InnAVasc Medical's main goal is to improve care for people with end-stage renal disease who use graft circuits for dialysis.
• In April 2023 - The first-in-human (FIH) aXess vascular graft trial (NCT04898153) was shown at the 13th Congress of the Vascular Access Society in Porto, Portugal. This was done by Xeltis, a company that makes transformative implants that make it possible for living vessels and valves to grow naturally. The first six months of the trial showed very promising results.

Key Vendors:

Top market players are

• Artegraft

Artegraft, Inc. makes tools and supplies for surgery. The company makes and sells biologic vascular grafts made from bovine carotid arteries. These grafts are usually put in people who need hemodialysis access.

• TERUMO CORPORATION

Terumo Corp. (Terumo) makes and sells medical care products, such as hospital and medical equipment and supplies. Pharmaceuticals, blood bags, single-use medical devices, dietary supplements, cardiovascular systems, vascular grafts, blood glucose monitoring systems, medical electronics, peritoneal dialysis, and digital thermometers are some of the company's most important product lines.

• BD

BD is one of the largest medical technology companies in the world. It is improving medical discovery, diagnostics, and the way care is given to make the world healthier. The company helps the heroes on the front lines of health care by creating new technology, services, and solutions that improve both clinical therapy for patients and clinical process for health care providers.

• Cook Group

Cook Group, Inc. is a holding company. Through its subsidiaries, the Company sells medical devices for interventional radiology, interventional cardiology, urology, neuroradiology, vascular medicine, critical care, and other fields.

• Medtronic

Medtronic Plc (Medtronic), which used to be called Medtronic Inc., is a medical technology company that makes and sells a wide range of medical devices and solutions.

• Cardinal Health

Cardinal Health Inc. (Cardinal Health) is a company that offers both products and services for health care. It sells brand-name and generic drugs, specialty medicines, over-the-counter health and consumer products, medical equipment, surgical devices, and laboratory products.

• Suokang

In 1987, Jiangyin Suokang Electronic Co.,Ltd. was set up. The company makes things like antennas, switches, and waveguides, which are all types of electronic parts.

• Maquet

Maquet Ltd. sells and services hospital equipment. The Company sells medical supplies, treatments, and services for use in operating rooms and intensive care units.

• LifeNet Health

LifeNet Health helps save lives, improve health, and give hope to tens of thousands of patients. LifeNet Health is the most trusted company in the world when it comes to organ transplants, organ procurement, and new innovations in bio-implant technologies and cellular therapies.

Segmentation Analysis:

The market is segmented on the basis of product, raw material, application and region.

By Product:

Depending on the item, the market is divided into Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, and Coronary Artery By-pass Graft. Most of the market was made up of endovascular stent-grafts. The growth of this segment is due to things like a rise in the number of people with coronary artery disease and chronic kidney disease (CKD), as well as the fact that vascular surgeons prefer endovascular stent graft. Also, the endovascular stent graft requires less surgery and less time to heal than other methods.

• Hemodialysis Access Graft
• Endovascular Stent Graft
• Peripheral Vascular Graft
• Coronary Artery By-pass Graft

By Raw Material:

The market is split into two groups based on the raw materials they use: synthetic raw materials and biological raw materials. The segment of the market with the biggest share is synthetic raw materials. This gives the graft more strength and makes it less likely to be rejected. Also, segmental growth will be helped by the high demand for synthetic raw materials, which have benefits like a longer lifespan and compatibility with blood.

• Synthetic Raw Material
• Biological Raw Material

By Application:

The market is split into Aneurysms, Kidney Failure, Vascular Occlusion, Coronary Artery Diseases, and Other Applications, based on how they are used. The aneurysms segment led the market because high blood pressure is so common and because advanced tissue-engineered grafts for pediatric congenital heart surgeries are now available. So, the demand for vascular grafts for aneurysms is likely to be driven by the rising demand for minimally invasive implants.

• Aneurysms
• Kidney Failure
• Vascular Occlusion
• Coronary Artery Diseases
• Other Applications

Regional Insights:

North America had a 30.2% share of the market in 2021, which was the most. This was because more people in the region were becoming aware of their health and there were more health care facilities for cardiovascular treatment in the region. The market is also growing because there are policies for getting money back and people are using more advanced technology.

Also, the growth of biomaterials vascular grafts is being driven by the use of biometric tools to accurately diagnose the disease, as well as technological advances and the discovery of tissue-engineered products. Over the next few years, the market is also expected to be driven by the ongoing research and development for making grafts out of advanced biomaterial.

Asia-Pacific, on the other hand, is expected to grow the fastest over the next few years. The growing number of people with heart diseases is putting a lot of stress on the area. Also, the number of people with chronic kidney disease, heart disease that has reached its end stage, diabetes, etc. is expected to drive market growth. Also, heart diseases that cause people to die too soon are expected to help the market grow.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Scope of Report:

Conclusion:

• This study analyzes the Global Artificial Vascular Graft Market, looks at trends, and makes predictions about the future to find the best places to invest right now.
• The report gives information about the market opportunity, as well as the key drivers and barriers that are affecting it.
• The size of the Global Artificial Vascular Graft Market is measured from 2022 to 2030 to show how financially stable the industry is.